Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
K
Kopran Ltd
Score 48/100• Risky
Kopran Ltd operates in a promising sector but faces significant challenges in growth consistency and market sentiment, making it a risky investment at this time.
Company’s Health73/100
Valuation 80/100 · PB 1.5664
Technical Avoid
1M -6.455% 6M -15.596% 1Y -43.583%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#226
View details ➜
K
KOBO Biotech Ltd
Score 48/100• Risky
KOBO Biotech Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
Company’s Health41/100
Valuation 100/100 · PB -0.0456
Technical Avoid
1M 3.913% 6M -15.517% 1Y -18.874%
Confidence100%
No promoter pledgeReasonable PB valuation
Thin margins
#227
View details ➜
K
Kimia Biosciences Ltd
Score 48/100• Risky
Kimia Biosciences Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health56/100
Valuation 20/100 · PB 16.2697
Technical Avoid
1M -7.545% 6M -13.793% 1Y -31.156%
Confidence100%
No promoter pledgeDecent revenue growth
High debt/equityThin margins
#228
View details ➜
K
Kabra Drugs Ltd
Score 48/100• Risky
Kabra Drugs Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
Company’s Health60/100
Valuation 80/100 · PB 1.7267
Technical Avoid
1M -3.155% 6M 62.094% 1Y 96.499%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#229
View details ➜
I
Ishita Drugs and Industries Ltd
Score 48/100• Risky
Ishita Drugs and Industries Ltd presents a risky investment profile with inconsistent growth and moderate profitability metrics. Caution is advised.
Company’s Health59/100
Valuation 60/100 · PB 2.0508
Technical Avoid
1M -2.192% 6M -7.627% 1Y -8.878%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#230
View details ➜
F
Fortis Malar Hospitals Ltd
Score 48/100• Decent
Fortis Malar Hospitals Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
Company’s Health52/100
Valuation 40/100 · PB 4.1156
Technical Avoid
1M 1.203% 6M -23.483% 1Y 17.603%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#231
View details ➜
C
Chandra Bhagat Pharma Ltd
Score 48/100• Risky
Chandra Bhagat Pharma Ltd presents a mixed outlook with several risks overshadowing its potential growth. Caution is advised for investors.
Company’s Health51/100
Valuation 80/100 · PB 1.0825
Technical Avoid
1M 5.659% 6M -22.517% 1Y -34.047%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#232
View details ➜
C
Chandan Healthcare Ltd
Score 48/100• Risky
Chandan Healthcare Ltd shows potential in a growing sector, but faces significant risks in terms of growth consistency and market valuation.
Company’s Health93/100
Valuation 20/100 · PB 5.7261
Technical Momentum
1M 38.267% 6M 43.515% 1Y 70.753%
Confidence100%
Low leverage (D/E)No promoter pledge
#233
View details ➜
C
Cell Point (India) Ltd
Score 48/100• Risky
Cell Point (India) Ltd shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
Company’s Health57/100
Valuation 100/100 · PB 0.463
Technical Avoid
1M 3.297% 6M -0.809% 1Y -43.558%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#234
View details ➜
B
Bal Pharma Ltd
Score 48/100• Decent
Bal Pharma Ltd shows potential but faces significant challenges in growth and market sentiment.
Company’s Health57/100
Valuation 80/100 · PB 1.6791
Technical Avoid
1M -9.802% 6M -22.938% 1Y -39.669%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEHigh debt/equity
#235
View details ➜
J
Johnson Pharmacare Ltd
Score 48/100• Risky
Johnson Pharmacare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health50/100
Valuation 100/100 · PB 0.754
Technical Avoid
1M -2.564% 6M -18.947% 1Y -31.25%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#236
View details ➜
G
GPT Healthcare Ltd
Score 48/100• Decent
GPT Healthcare Ltd shows potential but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health93/100
Valuation 40/100 · PB 4.9077
Technical Avoid
1M -4.319% 6M -11.841% 1Y -16.31%
Confidence100%
Low leverage (D/E)No promoter pledge
#237
View details ➜
G
Genpharmasec Ltd
Score 48/100• Risky
Genpharmasec Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health63/100
Valuation 80/100 · PB 1.5014
Technical Avoid
1M -10.204% 6M -12.376% 1Y -41.391%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#238
View details ➜
E
Evexia Lifecare Ltd
Score 48/100• Decent
Evexia Lifecare Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
Company’s Health22/100
Valuation 60/100 · PB 2.9315
Technical Avoid
1M -11.894% 6M -28.873% 1Y -51.905%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEHigh debt/equity
#239
View details ➜
C
Colinz Laboratories Ltd
Score 48/100• Decent
Colinz Laboratories Ltd shows decent potential with consistent growth and profitability metrics, but faces challenges in market sentiment and execution risks.
Company’s Health60/100
Valuation 80/100 · PB 1.115
Technical Avoid
1M 4.626% 6M -16.878% 1Y -23.709%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#240
View details ➜
Showing 226 to 240 of 301 (21 Pages)